ClinicalTrials.Veeva

Menu

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

BeiGene logo

BeiGene

Status and phase

Begins enrollment in 1 month
Phase 3

Conditions

Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Treatments

Drug: 5-fluorouracil (5-FU)
Drug: Cisplatin
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Subcutaneous Tislelizumab
Drug: Intravenous Tislelizumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT07043400
2024-519474-39-00 (EU Trial (CTIS) Number)
BGB-A317-316

Details and patient eligibility

About

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.

Enrollment

351 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically confirmed, locally advanced unresectable or metastatic gastric/ gastroesophageal junction (GEJ) adenocarcinoma.
  • No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer.
  • At least 1 measurable or nonmeasurable lesion per RECIST v1.1 as determined by investigator assessment.
  • Must be able to provide tumor tissues for biomarker assessment.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score ≤ 1.
  • Adequate organ function.
  • Women of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and ≥ 120 days after the last dose of tislelizumab.
  • Non-sterile males must be willing to use a highly effective method of birth control for the duration of the study and for ≥ 120 days after the last dose of tislelizumab.

Exclusion criteria

  • Squamous cell or undifferentiated or other histological type gastric cancer (GC)
  • Active leptomeningeal disease or uncontrolled brain metastasis. Patients with equivocal findings or with confirmed brain metastases are eligible for enrollment provided that they are asymptomatic and radiologically stable without the need for corticosteroid treatment for ≥ 4 weeks before randomization.
  • Diagnosis with gastric or GEJ adenocarcinoma with positive human epidermal growth factor receptor 2 (HER2).
  • Active autoimmune diseases or history of autoimmune diseases that may relapse.
  • Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (at least once a week) and/or diuretics within 7 days prior to randomization

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

351 participants in 2 patient groups

Arm A: Tislelizumab Subcutaneous + Chemotherapy
Experimental group
Description:
Participants will receive tislelizumab 300 mg subcutaneous (SC) injection on Day 1 of each 21-day cycle, followed by chemotherapy decided on an individual patient basis.
Treatment:
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Subcutaneous Tislelizumab
Drug: Capecitabine
Drug: 5-fluorouracil (5-FU)
Drug: Cisplatin
Arm B: Tislelizumab Intravenous Infusion + Chemotherapy
Active Comparator group
Description:
Participants will receive tislelizumab 200 mg intravenous infusion (IV) on Day 1 of each 21-day cycle, followed by chemotherapy decided on an individual patient basis.
Treatment:
Drug: Intravenous Tislelizumab
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Capecitabine
Drug: 5-fluorouracil (5-FU)
Drug: Cisplatin

Trial contacts and locations

87

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems